Elbit Imaging Ltd (EMITF)

[midastouch017]

Gamida received FDA classification
of "breakthrough treatment"

The company owned by Elbit Medical (25%) received
the classification for the Nicord due to improved absorption of blood cells in bone marrow transplantation in patients with malignant blood diseases

Elbit Medical Technologies reports that Gamida Ltd. held by the Company at the rate of 25% (22.5% fully diluted), announced that the Food and Drug Administration (FDA) has granted the classification of "breakthrough treatment" of the drug Nicord due to improved absorption of neutrophil blood cells by bone marrow transplant in patients with malignant blood diseases.

[Google auto translate]